Clinical Chemistry Analyzers (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 Market Impact)
|生物化學分析設備及系統:體外診斷市場分析·預測模式 Clinical Chemistry Analyzers (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 Market Impact)|
|出版日期: 2020年12月30日||內容資訊: 英文||
Clinical Chemistry Analyzers (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact) is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.
The model discusses in detail the impact of COVID-19 on Clinical Chemistry Analyzers market for the year 2020 and beyond. Clinical chemistry analyzers measure a broad array of biochemical parameters including diabetic factors, tumour markers, drugs of abuse or toxicology, therapeutic drugs for monitoring, specific proteins, lipids, and chemicals such as glucose, cholesterol, waste products, electrolytes, cofactors, and enzymes.
Due to their versatility, clinical chemistry analyzers are relied upon for diagnosis and monitoring of a range of different conditions including diabetes, cancer, cardiac disease, kidney disease, and liver disease. Clinical chemistry analyzer market is being driven by rises in the prevalence numerous diseases such as diabetes, cancer, and liver disease as well as aging populations. Model covers various types of Analyzers including Automated, Semi-Automated and Integrated.
Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.
Key Inclusions of the market model are -
Currently marketed Clinical Chemistry Analyzers and evolving competitive landscape -
Global, Regional and Country level market specific insights -
Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.
Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.
Companies covered: F. Hoffman-La Roche Ltd, Siemens Healthineers AG, Abbott Labs, Danaher Corp, Mindray Medical International Ltd, Randox Labs Ltd, Ortho-Clinical Diagnostics Inc and Others
Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina and Chile.
This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -
The model will enable you to -